Hosted on MSN18h
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450 Million-Plus for Trio of Cancer DrugsClinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...
News Medical on MSN1d
Certain genetic alterations may contribute to primary resistance of certain cancers to KRAS G12C inhibitorsThe KRAS G12C mutation is found in approximately 3% of all colorectal cancer cases and 1% to 2% of pancreatic adenocarcinoma ...
Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and ...
For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...
The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...
PESG Research releases a new market update on Silexion Therapeutics (NASDAQ: SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer ...
In patients with pancreatic ductal adenocarcinoma, KRAS G12D and G12V mutations hare associated with worse patient outcomes, ...
6don MSN
Multidrug resistance in cancer can be overcome by combining a drug that blocks a key enzyme with another anticancer drug, ...
In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...
"It's heartening to see the chairman address employees on his first full day, discussing concerns about targets and KRAs," ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback